Investigational drug · Phase 2
LY3549492
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Obesity, Overweight.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
10
Any phase or sponsor naming "LY3549492"
First trial start
2023
Nov 17, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY3549492", any sponsor or status.
Conditions studied
As listed on its trial records.
- Obesity
- Overweight
Approved drugs for the same conditions: Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "LY3549492" as an intervention, largest first.
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or OverweightPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT06143956 · 1,481 participants (planned) · Start Nov 17, 2023 · Primary completion Sep 2027
Drug: LY3305677; LY3841136 and 5 more · For: Obesity; Overweight
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 57 sites in all
- A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or OverweightPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT06683508 · 288 participants · Start Nov 13, 2024 · Primary completion Jan 7, 2026
Drug: LY3549492; Placebo · For: Obesity; Overweight
Sites: Chandler, Arizona; Phoenix, Arizona; Scottsdale, Arizona · 49 sites in all
- A Study of LY3549492 in Healthy Participants and Participants With Overweight or ObesityPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT07232732 · 120 participants · Start Oct 27, 2025 · Primary completion Jul 17, 2026
Drug: LY3549492 · For: Healthy; Obesity; Overweight
Sites: Daytona Beach, Florida; Dallas, Texas; Madison, Wisconsin
Eli Lilly and CompanyEli Lilly (LLY)
NCT06869018 · 92 participants · Start May 7, 2025 · Primary completion Mar 2, 2026
Drug: LY3549492; Placebo · For: Healthy; Type 2 Diabetes Mellitus (T2D)
Sites: Fukuoka, Japan; Hachiōji, Japan; Osaka, Japan · 4 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT05327595 · 80 participants · Start May 9, 2022 · Primary completion Apr 22, 2024
Drug: LY3549492; Placebo and 2 more · For: Diabetes Mellitus, Type 2
Sites: Neuss, Germany
Eli Lilly and CompanyEli Lilly (LLY)
NCT04758234 · 54 participants · Start Feb 22, 2021 · Primary completion Jan 10, 2022
Drug: LY3549492; Placebo · For: Healthy
Sites: Dallas, Texas
Eli Lilly and CompanyEli Lilly (LLY)
NCT07073170 · 36 participants · Start Jul 25, 2025 · Primary completion Jan 27, 2026
Drug: LY3549492; Placebo · For: Type 2 Diabetes
Sites: Beijing, China; Chengdu, China; Dongcheng District, China
Eli Lilly and CompanyEli Lilly (LLY)
NCT06194500 · 18 participants · Start Jan 3, 2024 · Primary completion Feb 15, 2024
Drug: [14C]-LY3549492; LY3549492 and 1 more · For: Healthy Male
Sites: Holbeck, United Kingdom
Eli Lilly and CompanyEli Lilly (LLY)
NCT07085468 · 1 participants · Start Jul 21, 2025 · Primary completion Aug 14, 2025
Drug: LY3549492; Placebo · For: Healthy
Sites: Scottsdale, Arizona; Covina, California; Northridge, California · 21 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07030868 · 1 participants · Start Jun 19, 2025 · Primary completion Jul 29, 2025
Drug: LY3549492; Placebo · For: Obesity; Overweight; Type 2 Diabetes
Sites: Phoenix, Arizona; Scottsdale, Arizona; Greenbrae, California · 42 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Obesity
- CagrilintidePhase 320 trials
Novo Nordisk · Obesity, Overweight, Type 2 Diabetes
- BerobenatidePF-08653944, MET097Phase 319 trials
Pfizer · Obesity, Overweight and/or Obesity, Overweight
- RetatrutideLY3437943Phase 316 trials
Eli Lilly · Obesity, Overweight, Type 2 Diabetes
- Maridebart cafraglutideAMG 133Phase 314 trials
Amgen · Obesity, Overweight, Obstructive Sleep Apnea
- EloralintideLY3841136Phase 313 trials
Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2
- HRS9531Phase 313 trials
Fujian Shengdi Pharmaceutical Co., Ltd. · Type 2 Diabetes, Chronic Management of Body Weight, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
- NNC0487-0111Phase 312 trials
Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea
- HRS-7535Phase 310 trials
Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.